National Adult Vaccination Program

R NAVPlogo wtagGSA created the National Adult Vaccination Program (NAVP) with the purpose of affecting policy and improving adult immunization rates to achieve the Healthy People 2020 Goals. The goals of NAVP seek to:

  1. diffuse evidence-based immunization information,
  2. affect policy through partnership,
  3. support GSA members making change in their practices to improve adult immunization rates, and
  4. drive sustainable solutions for gaps in knowledge and practice.

NAVP is developed by The Gerontological Society of America and supported by:

glaxosmithklineJohnson & Johnson Health Care Systems   merckpfizer   Sanofi PasteurSeqirus

Looking for GSA's COVID-19 Updates page? Click here.

Newsletters and Publications

NAVP Newsletter

To sign up for the monthly NAVP Newsletter, please email This email address is being protected from spambots. You need JavaScript enabled to view it..

  • October 2020: A Case in Logistics: Distribution and Administration of COVID-19 Vaccine
  • September 2020: Influenza Immunizations 2020–21: Communication, Clinical, Logistical Challenges
  • August 2020: COVID-19 – Planning for a Vaccine Rollout
  • July 2020: COVID-19 Vaccines – Who Will Take Them and Why
  • June 2020: COVID-19 – Testing the New Vaccine Technologies
  • May 2020: 2020–21 Influenza Season: Finding the Right Message
  • April 2020: Vaccine Communication – New Approaches Needed
  • March 2020: Special Issue on Coronavirus
  • February 2020: RSV – Infections a Problem, Vaccines a Challenge
  • January 2020: Driving Vaccine Uptake – A Psychological Approach
  • December 2019: ACIP finalizes Td/Tdap Advice and Adult Immunization Table for 2020
  • November 2019: Shifting to a Lifespan Approach for the Nation's Vaccine Plan
  • October 2019: Influenza Season 2019-2020
  • September 2019: AVAC Congressional Briefing Update
  • August 2019: ACIP Recommends Shared Decision Making
  • July 2019: Vaccines: Progress on Many Fronts (NAIIS Update)
  • June 2019: Measles: A Lot More than Spots
  • May 2019: Efficacy vs effectiveness
  • April 2019: Achieving Clarity on Pneumococcal Vaccines
  • March 2019: It's Complicated: Interactions Between People and Influenza Vaccine
  • February 2019: Understanding Vaccine Development
  • January 2019: Modulating Microbe/Immune Cell Interactions


Cover of the LTC and IZ publication Charting a Path to Increase Immunization Rates in the Post-Acute and Long-term Care Setting
agingandimmunity Aging and Immunity: The Important Role of Vaccines
whatshotimmuno Addressing the Complex Impact of Immunosenescence: The Value of Vaccination
The Advancing the National Adult Immunization Plan Through a Focus on Influenza Meeting Advancing the National Adult Immunization Plan Through a Focus on Influenza - Spring 2016
Vaccines older-adults-HRSA-edits-1 Health Benefits of Vaccines for Older Adults and Recommendations for Improving Older Adult Immunization Rates
  Comprehensive Report of the 2013 National Adult Vaccination Program Summit: Developing Champions and Building a Roadmap for Action to Achieve the Healthy People 2020 Goals for Adult Vaccination
navpfaqs Facts and Frequently Asked Questions about the National Adult Vaccination Program
whatshotimmunoacrossaging-tn What’s Hot in Immunizations Across the Aging Continuum—2013 Update
whatshotimmo-tn What’s Hot in Immunosenescence: Implications for Patient Care
pubstopracticeimmunizationrates-tn From Publication to Practice: A Look at Strategies to Improve Immunization Rates for Older Adults
whatshotnavp-tn What’s Hot in Immunizations Across the Aging Continuum
pubstopracticeinfluenzaolderadults-tn From Publication to Practice: An Interdisciplinary Look at New Developments in the Prevention and Treatment of Influenza in Older Adults
pparfall2012navp-tn Public Policy & Aging Report: Vaccination, Prevention, and Older Adults
calltoactionnavp-tn Call to Action—Reaching the Healthy People 2020 Goals for Adult Vaccination: Proceedings of the National Adult Vaccination Program Scientific Summit, April 2012

Download PDF files of archived NAVP Summit materials.

Webinars, Infographics, and Fact Sheets

Fact Sheets

GSA, in collaboration with Gerontological Advanced Practice Nurses Association (GAPNA) and AMDA, has launched a new project focused on improving education and awareness of enhanced influenza vaccine products.


Elevating Understanding of RSV in Older Adults
A GSA Webinar
Monday, August 31, 2020 | 12pm - 1pm Eastern
Archived webinar now available.

Respiratory syncytial virus, or RSV, causes 177,000 hospitalizations and 14,000 deaths in older adults each year. Those over 65, adults with chronic heart or lung disease, and adults with weakened immune systems are particularly at risk. Yet RSV remains underdiagnosed.

In this one-hour webinar, experts will share what is known about the prevalence, incidence, and impact of RSV in older adults. Participants will understand the symptoms and differential diagnoses for the disease and identify the reasons for underdiagnoses in older adults. Recent coding changes to improve diagnosis will be discussed, along with specific tips for communication techniques for providers at each phase of interaction with older adults who have RSV.


  • Robin Jump, MD, PhD – Case Western Reserve University, Louis Stokes Cleveland VA Medical Center
  • Lindsay Kim, MD, MPH – Centers for Disease Control and Prevention
  • Helen “Keipp” Talbot, MD, MPH – Vanderbilt University Medical Center

This webinar is supported by Johnson and Johnson Health Systems, Inc. Content is developed by GSA. Contact This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.

Understanding the Value of Enhanced Influenza Vaccine Products in Long-Term Care Settings
A GSA Webinar
Thursday, September 17, 2020 | 1pm - 2pm Eastern 
Free for everyone
Register here.

There are many benefits to preventing flu transmission in long-term care settings yet only about two-thirds of nursing home residents receive annual influenza vaccinations—one of the best known preventive strategies. The COVID-19 pandemic has further amplified the need for effective infection control in these settings. Compared with standard-dose influenza vaccines, enhanced influenza vaccines are not only more effective in preventing disease in older adults, they also provide a higher return on investment. This webinar is designed to help nursing home administrators, infection control teams, and other long-term care staff to (1) understand the benefits of using enhanced influenza vaccine products in residents and (2) learn practical tips that can help leadership and staff consistently apply immunization practices.

Presented by:

  • R. Gordon Douglas, MD, Chair, National Adult Vaccination Program Workgroup; Professor Emeritus, Weill Cornell Medical College (Moderator)
  • David H. Canaday, MD, Professor of Medicine, Case Western Reserve University; Associate Director, Geriatric, Research, Education, and Clinical Center (GRECC), Louis Stokes Cleveland VA Medical Center; Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center
  • Sherry A. Greenberg, PhD, RN, GNP-BC, FGSA, FAANP, FAAN, Associate Professor, Seton Hall University College of Nursing; President-Elect, Gerontological Advanced Practice Nurses Association
  • Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP, Professor, University of Maryland School of Nursing; Co-Director, Biology and Behavior Across the Lifespan Organized Research Center; Sonya Ziporkin Gershowitz Chair in Gerontology

This program was jointly developed by GSA, the Gerontological Advanced Practice Nurses Association, and AMDA – The Society for Post-Acute and Long-Term Care Medicine, with support from Sanofi.



GSA COVID Combined2

Immunization rates of staff and residents in long-term care facilities are low, even though strategies to improve rates are well known. Leaders gathered at a meeting hosted by GSA in May 2018 to discuss the issue and prioritize actions to improve rates. A shareable PDF is also available.


Immune function wanes in all adults—whether healthy or sick—as they age into their fifth decade and beyond. Their bodies become less adept at recognizing and stopping pathogens, and the ability to develop and maintain immunity declines. Also known as immunosenescence, age-related decline in immunity significantly contributes to the susceptibility of older adults to serious conditions, including influenza, pneumonia, and shingles.

The following infographics explain these concepts in easy-to-share formats. See the link below each infographic for a PDF copy. 

Infographic part1 final

 Click here for the PDF copy of Part 1: Immunity As We Age.

Infographic part2 final

 Click here for the PDF copy of Part 2: Shingles - A Case Study in Immunity and Vaccines.

ICAMP Training


From The Gerontological Society of America’s
National Adult Vaccination Program

ICAMP Academy is a 1⁄2-day multidisciplinary program for healthcare professionals who are committed to increasing adult vaccination rates, improving their patients’ health and improving quality metrics in their organization. ICAMP action planning aligns with the National Vaccine Advisory Committee (NVAC) Standards for Adult Immunization Practice and highlights the role of the immunization neighborhood.

To be notified when the next ICAMP is scheduled or to inquire about bringing ICAMP to your health system or conference, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

NAVP Workgroup Members

To help achieve its goals, the NAVP convened a workgroup of vaccine and policy experts to provide strategic recommendations and direction that focus on improving adult immunization rates and creating sustainable change.   

douglasR. Gordon Douglas, MD
R. Gordon Douglas is currently Professor Emeritus of Medicine at Weill Cornell Medical College; Chairman of Aeras (formerly Aeras Global TB Vaccine Foundation), a non-profit biotech company; Director of two biotech companies: Vical, Inc. (Chairman), and Novadigm (Chairman).  Dr. Douglas served as a consultant to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), from 1999-2011. He retired from Merck & Co. in 1999 after serving as President, Merck Vaccine Division, and a member of its Management Committee for 9 years.  Dr. Douglas is a graduate of Princeton University (1955) and Cornell University Medical College (1959). After internal medicine training at the New York Hospital and Johns Hopkins Hospital, and infectious disease training at NIAID, he served successively as Head of the Infectious Disease Unit, University of Rochester, (1970-1982) and Chairman, Department of Medicine and Physician-in-Chief at New York Hospital Cornell Medical Center (1982-1990) before joining Merck. He is author of over 190 original scientific publications dealing with viral pathogenesis, vaccines, and anti-virals, and was co-editor (with Gerald Mandell and John Bennett) of Principles and Practices of Infectious Diseases, the standard reference in the field. He is recipient of the R.R. Hawkins Award (Association of American Publishers, 1980), the H. Feldman Award (Infectious Disease Society of America, 1992), and the Maxwell Finland Award (National Foundation for Infectious Diseases, 2000). He is a member of the Institute of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and the American Clinical and Climatologic Association. He recently retired as trustee of McCarter Theater, the National Foundation for Infectious Diseases, and the Lyme Academy College of Fine Arts.  He served as President of the Class of 1955 at Princeton University from 2005 until 2010.

cantuMichelle Cantu, MPH
Michelle Cantu is the Director for Infectious Disease and Immunization at the National Association of County and City Health Officials (NACCHO), a nonprofit representing nearly 3,000 local health departments nationwide. At NACCHO, Michelle leads the Immunization Program to engage local health departments to increase their capacity in prevention and control of vaccine preventable diseases. She oversees the management of the immunization advisory workgroup, national partnerships among multidisciplinary groups addressing VPDs, and evaluation to further enhance programmatic strategies, policies, and activities. Michelle has over 12 years of leadership experience in public health with a focus on infectious disease prevention. Prior to her role at NACCHO, Michelle was the Director of Community-Based STD Prevention Initiatives at Essential Access Health (formerly California Family Health Council) in Los Angeles, California. In that role, she worked with a diverse group of health centers on quality improvement programs related to reproductive health delivery, services, and data. She obtained her Master of Public Health (MPH) from the Johns Hopkins Bloomberg School of Public Health with a focus in infectious diseases and epidemiology and holds a Bachelor of Arts from the University of Texas at Austin.

dcasanovaDanielle Casanova, MBA
Danielle Casanova is responsible for establishing the AMGA population health initiatives’ overall vision, and she provides oversight on all collaborative and acclaim award activities. She leads strategic direction and planning of current and future quality collaboratives and the acclaim award program. She has spent 17 years in total, working for healthcare associations developing, training, and implementing national healthcare programs for the American Diabetes Association and national population health and quality programs for AMGA. Ms. Casanova received her undergraduate degree in Biology with a concentration in PreMedicine and has a master’s degree in Business Administration with a concentration in Healthcare Management.  

gravensteinStefan Gravenstein, MD, MPH
A geriatrician, former John Franklin Chair of Geriatrics and Director of the Glennan Center for Geriatrics and Gerontology at Eastern Virginia Medical School (1996-2007), and Director of Center for Geriatrics and Palliative Care at University Hospitals in Cleveland (2014-2017), he is now Professor in the departments of Medicine and Health Services Policy and Practice at Brown's schools of medicine and public health, and Director, Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University. Dr. Gravenstein has a long-standing interest in immunity, inflammation, cardiovascular outcomes and aging especially in the context of vaccines and the long-term care setting, and the topic of the majority of his publications. He also has a specific interest in quality improvement in health care, the culture of care, antimicrobial stewardship, and how to improve care transitions. He was Clinical Director at Healthcentric Advisors, Medicare's Quality Improvement Organization for New England from 2007 to 2019.

resnickBarbara Resnick, PhD, RN, CRNP    
Barbara Resnick received a bachelor of science in nursing from the University of Connecticut, a master of science in nursing from the University of Pennsylvania, and a doctoral degree in nursing from the University of Maryland.

Dr. Resnick’s research focus has been on motivation of older adults, particularly with regard to performance of functional activities and engaging in regular exercise.  Included among her research activities have been several federally funded projects focused on older adults such as Testing the Reliability and Validity of the Exercise Plus Program Post Hip Fracture (NIA RO1 AG17082-01) and Testing the Effectiveness of the Res-Care Intervention (AHRQ R01 HS/MH 13372-010). In addition, Dr. Resnick has numerous projects focused on testing exercise interventions across a variety of clinical areas: community dwelling older adults in a continuing care retirement community and minority older adults in senior centers.  Similarly, Dr. Resnick is the primary investigator on several measurement studies related to physical activity in older adults. She has authored over 100 manuscripts, numerous book chapters on both clinical and research topics relevant to the care of older adults, and she recently authored a book on restorative care nursing.  Dr. Resnick is a fellow in the Academy of Nursing and the American Academy of Nurse Practitioners, received the 2003 Distinguished Faculty Research Award from the University of Maryland, and numerous awards for both her clinical work as well as her research.

schaffnerWilliam Schaffner, MD    
William Schaffner is Chairman of the Department of Preventive Medicine as well as Professor of Infectious Diseases in the Department of Medicine at the Vanderbilt University School of Medicine.  His primary interests are infectious diseases and their prevention.  Dr. Schaffner has worked extensively on the effective use of vaccines in both pediatric and adult populations.  He is a strong proponent of collaboration between academic medical centers and public health institutions.

Dr. Schaffner is a liaison representative to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) and is a member of the Immunization Technical Advisory Committee of the American College of Physicians.  He is a former member of the National Vaccine Advisory Committee (NVAC), Past President of the Society for Healthcare Epidemiology of America, and a former Councilor and Secretary of the Board of Directors of the Infectious Diseases Society of America.  Currently, he is President of the National Foundation for Infectious Diseases.  Dr. Schaffner is a consultant in public health policy and communicable disease control for numerous national and local institutions including the CDC, the World Health Organization, and the Tennessee Department of Health.  Dr. Schaffner is a member of numerous professional societies and has written over 400 scientific articles and textbook chapters.  He often is called upon to communicate about public health issues in the print media and television.

After graduation from Yale in 1957, Dr. Schaffner attended the University of Freiburg, Germany, as a Fulbright Scholar.  In 1962, he graduated from Cornell University Medical College and completed an internship, residency training, and a fellowship in Infectious Diseases at Vanderbilt University Medical Center.  He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the CDC  in Atlanta for 2 years (1966-1968), returning to Vanderbilt after that tour of duty.

Share This Page!

Print Page